Jun. 9 at 1:07 AM
$BHVN If Biohaven’s muscle-sparing obesity monotherapy delivers clean data this fall, it will be one of the largest clinical breakthroughs in modern pharmaceutical history. It would transform Biohaven from a speculative
$1.6 billion biotech company into the sole owner of a multi-billion-dollar therapeutic monopoly. The global weight-loss market is aggressively on track to reach
$100 billion. Right now, every major pharmaceutical giant that missed the initial GLP-1 wave (like Pfizer, Sanofi, or Bristol Myers Squibb) is desperately hunting for a way in. Because Biohaven’s drug could provides an all-in-one fat-melting and muscle-retaining profile without the severe gastrointestinal side effects or the logistical hassle of two separate companion injections, a successful Phase 2 readout would immediately position Biohaven for greatness!
